Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rintatolimod - Hemispherx Biopharma

Drug Profile

Rintatolimod - Hemispherx Biopharma

Alternative Names: Ampligen; Atvogen; Mismatched double-stranded RNA - Hemispherx Biopharma; Poly I:Poly C12U; Poly I:polyC12U; poly(I) poly(C12,U); Rintamod; Vaccine-adjuvant-poly-I-polyC12U; Vaccine-adjuvant-rintatolimod

Latest Information Update: 13 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hemispherx Biopharma
  • Developer Hemispherx Biopharma; National Cancer Institute (USA); Roswell Park Cancer Institute; United States Army Medical Research Institute of Infectious Diseases; University of Pittsburgh
  • Class Adjuvants; Antineoplastics; Antivirals; Oligonucleotides
  • Mechanism of Action HIV replication inhibitors; Interferon stimulants; Ribonuclease stimulants; RNA synthesis inhibitors; Toll-like receptor 3 agonists; VP35 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cell carcinoma; Ebola virus infections; HIV infections; Chronic fatigue syndrome; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Chronic fatigue syndrome
  • Phase II Colorectal cancer
  • Phase I/II Breast cancer; Influenza virus infections; Ovarian cancer; Peritoneal cancer
  • Clinical Phase Unknown Pancreatic cancer
  • Preclinical Ebola virus infections; West Nile virus infections; Zika virus infection
  • Research Coronavirus infections; Influenza A virus infections
  • Suspended HIV infections
  • No development reported Hepatitis B; Malignant melanoma; Renal cell carcinoma
  • Discontinued Smallpox; Western equine encephalitis virus infections

Most Recent Events

  • 11 Feb 2019 University of Pittsburgh in collaboration with Merck & Co and Hemispherx Biopharma initiates enrolment in a phase-I/II trial for Ovarian cancer (Combination therapy, Neoadjuvant therapy, Second-line therapy or greater) in USA (NCT03734692)
  • 08 Jan 2019 Institutional Review Board approves the initiation of a clinical trial of rintatolimod in Breast cancer
  • 08 Jan 2019 Hemispherx Biopharma and Roswell Park Cancer Center plan a clinical trial for Breast cancer (Inoperable/unresectable, Combination therapy, Metastatic disease, Second line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top